ScreenerHero

PCSAProcessa Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · processapharmaceuticals.com
2.080USD-3.26%Mkt Cap: 5.81M $P/E: 3.20

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap5.81M $
Enterprise Value4.99M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.56M $
Revenue/Share—
Last Price2.080 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)3.20
P/E (Forward)-0.57
PEG—
EV/EBITDA-0.34
EV/Revenue—
P/S—
P/B2.26
EPS (TTM)0.65
EPS (Forward)-3.75
52W Range
1.7603% of range14.25
52W High14.25 USD
52W Low1.760 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-243.20%
ROA-173.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.39M $
CapEx (TTM)850.00K $
FCF Margin—
FCF Yield-119.76%
Net Debt-1.69M $
Net Debt/EBITDA0.12
Balance Sheet
Debt/Equity0.00
Current Ratio0.98
Quick Ratio0.85
Book Value/Sh0.9490 USD
Cash/Share0.6150 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 23, 2019
Splits
Last Split1:25
Split DateDec 17, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.79M
Float2.64M
Insiders12.35%
Institutions10.78%
Short Interest
Short Ratio0.4d
Short % Float7.30%
Short % Out.6.44%
Shares Short215.85K
Short (prev mo.)86.05K
Technical
SMA 502.221 (-6.3%)
SMA 2003.321 (-37.4%)
Beta0.96
S&P 52W Chg18.16%
Avg Vol (30d)446.17K
Avg Vol (10d)57.32K
Technical Indicators
RSI (14)42.9
MACD-0.0121
MACD Signal0.0268
MACD Hist.-0.0390
BB Upper2.976 USD
BB Middle2.386 USD
BB Lower1.797 USD
BB Width49.40%
ATR (14)0.2410 USD
Vol Ratio (20d)0.11x